Neurocrine Biosciences
Clinical trials sponsored by Neurocrine Biosciences, explained in plain language.
A biopharmaceutical company focused on neurological and endocrine disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for uncontrolled muscle movements: valbenazine trial targets stubborn TD symptoms Results expected Jan 2027 (estimated)
- New pill could tame involuntary twitching in mental health patients Results expected Feb 2027 (estimated)
- New depression pill shows promise in Late-Stage trial Results expected Jul 2027 (estimated)
- New depression pill shows promise in Late-Stage trial Results expected Jul 2027 (estimated)
- New depression pill shows promise in Late-Stage trial Results expected Jul 2027 (estimated)
-
Promising seizure drug study halted early
Disease control Stopped earlyThis study looked at the long-term safety of the drug NBI-921352 for people with a rare genetic seizure disorder called SCN8A-DEE. It was an extension of an earlier study, and participants took the drug alongside their usual seizure medications. The study was stopped early and on…
Phase 2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Epilepsy drug study for kids halted early: what we know
Disease control Stopped earlyThis study looked at the long-term safety of a drug called NBI-827104 in children with a rare epilepsy that causes seizures during sleep. The trial was stopped early and only enrolled 19 children, so the results are limited. The main goal was to see how many children had serious …
Phase 2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Promising epilepsy drug trial halted early – what we know
Disease control Stopped earlyThis study tested an experimental drug called NBI-921352 in people aged 2 to 21 with a rare, severe form of epilepsy caused by a change in the SCN8A gene. The goal was to see if adding this drug to their current seizure medicines could reduce how often they had seizures. The tria…
Phase 2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC